AU2012249322B2 - HSP90 combination therapy - Google Patents

HSP90 combination therapy Download PDF

Info

Publication number
AU2012249322B2
AU2012249322B2 AU2012249322A AU2012249322A AU2012249322B2 AU 2012249322 B2 AU2012249322 B2 AU 2012249322B2 AU 2012249322 A AU2012249322 A AU 2012249322A AU 2012249322 A AU2012249322 A AU 2012249322A AU 2012249322 B2 AU2012249322 B2 AU 2012249322B2
Authority
AU
Australia
Prior art keywords
hsp90
sep
protein
cancer
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012249322A
Other languages
English (en)
Other versions
AU2012249322A1 (en
Inventor
Gabriela Chiosis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2012249322A1 publication Critical patent/AU2012249322A1/en
Priority to AU2017272303A priority Critical patent/AU2017272303A1/en
Application granted granted Critical
Publication of AU2012249322B2 publication Critical patent/AU2012249322B2/en
Priority to AU2020200262A priority patent/AU2020200262A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
AU2012249322A 2011-04-28 2012-04-27 HSP90 combination therapy Ceased AU2012249322B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017272303A AU2017272303A1 (en) 2011-04-28 2017-12-08 HSP90 combination therapy
AU2020200262A AU2020200262A1 (en) 2011-04-28 2020-01-14 HSP90 combination therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161480198P 2011-04-28 2011-04-28
US61/480,198 2011-04-28
PCT/US2012/035690 WO2012149493A2 (en) 2011-04-28 2012-04-27 Hsp90 combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017272303A Division AU2017272303A1 (en) 2011-04-28 2017-12-08 HSP90 combination therapy

Publications (2)

Publication Number Publication Date
AU2012249322A1 AU2012249322A1 (en) 2013-12-12
AU2012249322B2 true AU2012249322B2 (en) 2018-01-04

Family

ID=47073116

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012249322A Ceased AU2012249322B2 (en) 2011-04-28 2012-04-27 HSP90 combination therapy
AU2017272303A Abandoned AU2017272303A1 (en) 2011-04-28 2017-12-08 HSP90 combination therapy
AU2020200262A Abandoned AU2020200262A1 (en) 2011-04-28 2020-01-14 HSP90 combination therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017272303A Abandoned AU2017272303A1 (en) 2011-04-28 2017-12-08 HSP90 combination therapy
AU2020200262A Abandoned AU2020200262A1 (en) 2011-04-28 2020-01-14 HSP90 combination therapy

Country Status (12)

Country Link
US (2) US20140315929A1 (enExample)
EP (1) EP2701747A4 (enExample)
JP (3) JP6363502B2 (enExample)
KR (2) KR102027448B1 (enExample)
CN (2) CN109498812A (enExample)
AU (3) AU2012249322B2 (enExample)
BR (1) BR112013027448A2 (enExample)
CA (1) CA2833390A1 (enExample)
EA (1) EA201391587A1 (enExample)
MX (1) MX2013012183A (enExample)
NZ (1) NZ618062A (enExample)
WO (1) WO2012149493A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140294725A1 (en) 2011-07-08 2014-10-02 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP3498701B1 (en) 2012-12-21 2023-02-22 Epizyme Inc Prmt5 inhibitors and uses thereof
US10071130B2 (en) 2013-12-12 2018-09-11 The University Of Chicago Methods and compositions related to Hsp90 inhibitors and breast cancer
EP3086792B1 (en) 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
MX2016014365A (es) * 2014-05-02 2017-04-27 Wistar Inst Terapias combinadas dirigidas a mitocondrias para la terapia contra cancer.
CN107110869B (zh) 2014-09-17 2021-08-10 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
US9754080B2 (en) 2014-10-21 2017-09-05 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cardiovascular disease conditions
US10073952B2 (en) 2014-10-21 2018-09-11 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10388407B2 (en) 2014-10-21 2019-08-20 uBiome, Inc. Method and system for characterizing a headache-related condition
US10777320B2 (en) 2014-10-21 2020-09-15 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
US10265009B2 (en) 2014-10-21 2019-04-23 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome taxonomic features
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10169541B2 (en) 2014-10-21 2019-01-01 uBiome, Inc. Method and systems for characterizing skin related conditions
US10395777B2 (en) 2014-10-21 2019-08-27 uBiome, Inc. Method and system for characterizing microorganism-associated sleep-related conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9758839B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with microbiome functional features
US10793907B2 (en) 2014-10-21 2020-10-06 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US10346592B2 (en) 2014-10-21 2019-07-09 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
EP3209803A4 (en) 2014-10-21 2018-06-13 Ubiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics
US10311973B2 (en) 2014-10-21 2019-06-04 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for autoimmune system conditions
US10409955B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for locomotor system conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US9760676B2 (en) 2014-10-21 2017-09-12 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
US11783914B2 (en) 2014-10-21 2023-10-10 Psomagen, Inc. Method and system for panel characterizations
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10789334B2 (en) 2014-10-21 2020-09-29 Psomagen, Inc. Method and system for microbial pharmacogenomics
US10246753B2 (en) 2015-04-13 2019-04-02 uBiome, Inc. Method and system for characterizing mouth-associated conditions
CN107849616B (zh) * 2015-04-13 2022-03-29 普梭梅根公司 用于功能特征相关的状况的微生物组来源的表征、诊断和治疗的方法及系统
CN106265660B (zh) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 A674563在携带flt3突变型基因的急性白血病中的用途
CN106349180B (zh) * 2015-07-14 2020-05-19 上海翰森生物医药科技有限公司 4,5-二苯基异噁唑衍生物及其制备方法和应用
JP7187035B2 (ja) * 2016-08-03 2022-12-12 アールイーエムディー バイオセラピューティクス，インコーポレイテッド 癌を治療するためのグルカゴン受容体アンタゴニストとｐｉ３ｋ経路阻害剤との組み合わせ
RU2019127350A (ru) * 2017-02-03 2021-03-03 ЭйАй ТЕРАПЬЮТИКС, ИНК. Способы лечения рака с использованием ингибиторов hsp90
JP2020524156A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法
IL299893A (en) 2017-06-20 2023-03-01 Madrigal Pharmaceuticals Inc prescribed medications
JP7558167B2 (ja) 2018-12-03 2024-09-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム オリゴベンズアミド類似体およびがん処置におけるそれらの使用
CN109554343B (zh) * 2018-12-29 2022-04-19 吉林大学 一种适于神经元粘附与存活的涂层材料及制备方法
CN111467472B (zh) * 2020-04-21 2020-12-25 南京中医药大学 一种靶向肿瘤相关巨噬细胞的免疫调节微球制剂及其制备方法与应用
WO2021252490A2 (en) * 2020-06-11 2021-12-16 The Children's Medical Center Corporation Use of heat shock protein inhibitors for the treatment of neurodevelopmental disorders
CN116615422A (zh) * 2020-10-14 2023-08-18 珃诺生物医药科技(杭州)有限公司 用于靶向蛋白降解的方法和组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060328A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO2007035963A2 (en) * 2005-09-23 2007-03-29 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
JP5721949B2 (ja) * 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
EP2491923A3 (en) * 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
WO2008114812A1 (ja) * 2007-03-19 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Jak阻害剤
KR20150091434A (ko) * 2007-07-30 2015-08-10 아디아 바이오사이언스즈 인크. 다형체를 포함하는, ｍｅｋ의 억제제로서의 ｎ-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
US20100310563A1 (en) * 2007-11-30 2010-12-09 Bumm Thomas G P Methods for treating induced cellular proliferative disorders
WO2010006072A2 (en) * 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US20110319415A1 (en) * 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
JP2012510442A (ja) * 2008-11-28 2012-05-10 ノバルティス アーゲー Ｈｓｐ９０阻害剤の組合せ
US8669289B2 (en) * 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
EP2443123B1 (en) * 2009-06-15 2017-04-05 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
ES2608670T3 (es) * 2009-08-17 2017-04-12 Memorial Sloan-Kettering Cancer Center Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos
NZ604040A (en) * 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2714038A1 (en) * 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060328A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Caldas-Lopes et al, Proceedings of the National Academy of Sciences (2009), Vol. 106, No. 20, Pages 8368-8373 *
Kamalika Moulick ET AL, Cancer Research (2009), Vol. 69, No. 9 Supplement, AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO, URL: http://cancerres.aacrjournals.org/content/69/9_Supplement/LB-86.abstract *
Normant et al, "The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models", Oncogene (2011), Vol. 30, No. 22, Pages 2581-2586 *
Taldone et al, "Design, synthesis, and evaluation of small molecule Hsp90 probes", Bioorganic & Medicinal Chemistry (2011), Vol. 19, No. 8, Pages 2603-2614 *

Also Published As

Publication number Publication date
AU2017272303A1 (en) 2018-01-04
JP6363502B2 (ja) 2018-07-25
JP2014523516A (ja) 2014-09-11
CA2833390A1 (en) 2012-11-01
BR112013027448A2 (pt) 2020-09-01
WO2012149493A3 (en) 2014-05-08
MX2013012183A (es) 2014-05-27
JP2017036288A (ja) 2017-02-16
CN109498812A (zh) 2019-03-22
KR20140059757A (ko) 2014-05-16
EA201391587A1 (ru) 2014-08-29
KR20190112839A (ko) 2019-10-07
WO2012149493A2 (en) 2012-11-01
JP2018153194A (ja) 2018-10-04
US20220074941A1 (en) 2022-03-10
AU2020200262A1 (en) 2020-02-06
JP6375345B2 (ja) 2018-08-15
NZ618062A (en) 2016-04-29
US20140315929A1 (en) 2014-10-23
CN103998935B (zh) 2018-10-16
KR102196424B1 (ko) 2020-12-30
CN103998935A (zh) 2014-08-20
AU2012249322A1 (en) 2013-12-12
EP2701747A4 (en) 2015-04-01
KR102027448B1 (ko) 2019-10-01
EP2701747A2 (en) 2014-03-05

Similar Documents

Publication Publication Date Title
US20220074941A1 (en) Hsp90 combination therapy
Rais et al. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug
Kohsaka et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression
Fischer et al. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors
Ameratunga et al. To cycle or fight—CDK4/6 inhibitors at the crossroads of anticancer immunity
Colbert et al. CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer
Valvezan et al. IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex
Mpilla et al. PAK4-NAMPT dual inhibition sensitizes pancreatic neuroendocrine tumors to everolimus
Frett et al. Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition: Miniperspective
Zemanova et al. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells
Li et al. Developing SHP2-based combination therapy for KRAS-amplified cancer
Chen et al. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma
Nayar et al. Identification of a nucleoside analog active against adenosine kinase–expressing plasma cell malignancies
US20250127783A1 (en) Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1), combinations and uses thereof
EP3329923A1 (en) The potential of crbn-independent imid resensitization by epigenetic therapy
Hagbi-Levi et al. Identification of Dinaciclib and Ganetespib as anti-inflammatory drugs using a novel HTP screening assay that targets IFNγ-dependent PD-L1
HK40006457A (en) Hsp90 combination therapy
Lehto Finding synergies for cancer treatment: new ways to modulate DNA damage repair by CX3CR1 and PFKFB3 inhibition
Stern et al. Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors
Diehl Investigation of the Kinome in Pancreatic Ductal Adenocarcinoma
Villarreal Exploring novel roles of metabolic enzymes MTHFD2 and PFKFB3 in cancer genome stability and their potential as anticancer therapeutic targets
Kiraz Sensitization of Philadelphia positive acute lymphoblastic leukemia cells resistant to imatinib by targeting sphingolipid metabolism
Manchester Identifying Combinatorial Drug Targets for Ras Pathway-Driven Melanomas
Robb Evaluation of Aminopyrazole Analogs as Cyclin-Dependent Kinase Inhibitors for Colorectal Cancer Therapy
Ladds p53 transcriptional activity as a tool to uncover novel and diverse druggable targets in cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired